North America Hemostatic Sealants Arterial Surgery Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Hemostatic sealants used in arterial surgery are specialized medical devices designed to accelerate the body's natural clotting process and achieve hemostasis during vascular procedures. These products are critical in reducing operative time, minimizing blood loss, and improving patient outcomes in complex arterial surgeries including coronary artery bypass grafting, peripheral arterial interventions, and carotid endarterectomies. The North American market encompasses the United States, Canada, and Mexico, with product offerings ranging from topical hemostatic agents to tissue sealants that provide both hemostatic and sealing functions.

• •Market valued at $3.19 billion in 2025 across North America
• •Products serve arterial procedures including coronary, peripheral, and carotid surgeries
• •Includes both topical hemostats and adhesive tissue sealants

The primary growth catalyst stems from the rising prevalence of cardiovascular diseases across North America, driven by aging populations and lifestyle-related health conditions that increase demand for arterial interventions. Advancements in minimally invasive surgical techniques have expanded the application scope for hemostatic sealants, while ongoing product innovations in biocompatibility and efficacy continue to drive adoption rates among surgical teams. Additionally, favorable reimbursement policies in the United States and growing awareness of the clinical benefits of hemostatic agents support market expansion.

• •Aging population increases incidence of arterial diseases requiring surgical intervention
• •Growing adoption of minimally invasive surgical procedures
• •Favorable clinical outcomes data supporting hemostatic agent utilization

The market is segmented by product type into fibrin-based sealants derived from biological sources and synthetic or polymer-based sealants offering mechanical hemostasis properties. Application categories include open surgical procedures and minimally invasive interventions, with disease indications spanning coronary artery disease, peripheral artery disease, and other vascular conditions. Geographically, the United States dominates the market due to its sophisticated healthcare system and high procedural volumes, while Canada and Mexico represent smaller but growing segments driven by healthcare modernization initiatives.

• •Product categories include fibrin-based biological and synthetic polymer-based sealants
• •End users primarily consist of hospitals and ambulatory surgical centers
• •United States represents the largest regional market share

What are the recent trends and outlook?

The market is experiencing a shift toward synthetic and recombinant hemostatic products that reduce the risk of disease transmission associated with biological derivatives while maintaining superior hemostatic performance. Rising surgical volumes, particularly in ambulatory settings, are creating demand for user-friendly, cost-effective hemostatic solutions that can be efficiently integrated into procedural workflows. Future growth will likely be supported by product innovation, expansion into emerging surgical applications, and continued healthcare infrastructure investment across North America.

• •Growing preference for synthetic and recombinant hemostatic agents
• •Increasing utilization in ambulatory and outpatient surgical settings
• •Ongoing development of combination products integrating hemostatic and sealing functions